Details for New Drug Application (NDA): 022577
✉ Email this page to a colleague
The generic ingredient in VIREAD is tenofovir disoproxil fumarate. There are forty-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the tenofovir disoproxil fumarate profile page.
Summary for 022577
Tradename: | VIREAD |
Applicant: | Gilead Sciences Inc |
Ingredient: | tenofovir disoproxil fumarate |
Patents: | 0 |
Pharmacology for NDA: 022577
Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Suppliers and Packaging for NDA: 022577
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
VIREAD | tenofovir disoproxil fumarate | POWDER;ORAL | 022577 | NDA | Gilead Sciences, Inc. | 61958-0403 | 61958-0403-1 | 1 BOTTLE, PLASTIC in 1 CARTON (61958-0403-1) / 60 g in 1 BOTTLE, PLASTIC |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;ORAL | Strength | 40MG/SCOOPFUL | ||||
Approval Date: | Jan 18, 2012 | TE: | RLD: | Yes |
Expired US Patents for NDA 022577
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Gilead Sciences Inc | VIREAD | tenofovir disoproxil fumarate | POWDER;ORAL | 022577-001 | Jan 18, 2012 | ⤷ Subscribe | ⤷ Subscribe |
Gilead Sciences Inc | VIREAD | tenofovir disoproxil fumarate | POWDER;ORAL | 022577-001 | Jan 18, 2012 | ⤷ Subscribe | ⤷ Subscribe |
Gilead Sciences Inc | VIREAD | tenofovir disoproxil fumarate | POWDER;ORAL | 022577-001 | Jan 18, 2012 | ⤷ Subscribe | ⤷ Subscribe |
Gilead Sciences Inc | VIREAD | tenofovir disoproxil fumarate | POWDER;ORAL | 022577-001 | Jan 18, 2012 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription